Trial Profile
Study to Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary) ; Antivirals; Azithromycin; Hydroxychloroquine; Lopinavir/ritonavir
- Indications COVID 2019 infections; Pneumonia
- Focus Therapeutic Use
- Acronyms COVID-BioB
- 23 Dec 2022 Planned End Date changed from 19 Mar 2023 to 19 Mar 2024.
- 23 Dec 2022 Planned primary completion date changed from 19 Mar 2023 to 19 Mar 2024.
- 21 Dec 2021 Planned number of patients changed from 1000 to 6000.